<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HF287DFEBE6D1436B914F5CF55B03EA0A" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6109 IH: Producing Incentives for Long-term production of Lifesaving Supply of Medicine Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-10-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6109</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231026">October 26, 2023</action-date><action-desc><sponsor name-id="T000478">Ms. Tenney</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes.</official-title></form><legis-body id="H62F75B8F3DD24D2E9296B814C0E3EA96" style="OLC"> 
<section id="H901B580E5530485684C9F44851A53BD2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Producing Incentives for Long-term production of Lifesaving Supply of Medicine Act</short-title></quote> or the <quote><short-title>PILLS Act</short-title></quote>.</text></section> <section id="H1C535AD977E04A46A33C7455DAB20D91"><enum>2.</enum><header>Generic drugs and biosimilars production credit</header> <subsection id="HDA87B20281904FBB86370D91CF7105DE"><enum>(a)</enum><header>In general</header><text>Subpart D of part IV of chapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 amended by adding at the end the following new section: </text> 
<quoted-block id="H84D4CE758AA743D8B3A6740C384428B8" style="OLC"> 
<section id="HFBE7C6C05C8D4DC295D7691AFFA4A731"><enum>45BB.</enum><header>Generic drugs and biosimilars production credit</header> 
<subsection id="H00040355208E4EF88FC14F3F9A867206"><enum>(a)</enum><header>In general</header> 
<paragraph id="HEDC48B57D88649B281DA10AF06EC0366"><enum>(1)</enum><header>Allowance of credit</header><text>For purposes of section 38, the generic drugs and biosimilars production credit for any taxable year is an amount equal to the credit amount determined under subsection (b) with respect to each eligible component which is—</text> <subparagraph id="H8E50798D5D6B4CFAA09156E53540D12C"><enum>(A)</enum><text>produced by the taxpayer in the United States, and</text></subparagraph> 
<subparagraph id="H558A92E49BC54C049E0152BEF41C7A11"><enum>(B)</enum><text display-inline="yes-display-inline">sold by such taxpayer to an unrelated person during the taxable year.</text></subparagraph></paragraph> <paragraph id="H8509374EB5BC40EFBCC3B7E06110EDAC"><enum>(2)</enum><header>Production and sale must be in trade or business; unrelated person</header><text>Rules similar to the rules of paragraphs (2) and (3) of section 45X(a) shall apply.</text></paragraph> 
<paragraph id="HE0F6EC0C51EC4A3F9AC5C76A9C839F08"><enum>(3)</enum><header>Disallowance of credit</header><text display-inline="yes-display-inline">The credit under this subsection shall not be allowed to any taxpayer which, at any time during the taxable year, was a foreign entity of concern (as defined in section 9901(8) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<external-xref legal-doc="usc" parsable-cite="usc/15/4651">15 U.S.C. 4651</external-xref>)).</text></paragraph> </subsection> <subsection id="HEEEB636688D54302833E758C490A4679"><enum>(b)</enum><header>Credit amount</header> <paragraph id="HC639FD1FC02C437BA4D154A113A2822F"><enum>(1)</enum><header>In general</header><text>Subject to paragraph (4), the amount determined under this subsection with respect to any eligible component shall be an amount equal to—</text> 
<subparagraph id="H3F4758E884594C47898414EC421EC82F"><enum>(A)</enum><text>the value added to such component by the taxpayer, multiplied by</text></subparagraph> <subparagraph id="H60B3EC6773094CC79610A95DB96E09D2"><enum>(B)</enum><text>the base credit percentage.</text></subparagraph></paragraph> 
<paragraph id="HE149D726786741F184C5EEF41C8E692F" commented="no"><enum>(2)</enum><header>Value added</header><text>The value added to a component by a taxpayer is an amount equal to—</text> <subparagraph id="HBBE0D5C52355476EAACAEC18A3BB4714" commented="no"><enum>(A)</enum><text>the gross receipts received by the taxpayer from the sale of the eligible component, minus</text></subparagraph> 
<subparagraph id="HEC1FB920AF8B4573AC57B2429D1CD017" commented="no"><enum>(B)</enum><text>the cost of eligible components purchased from an unrelated person in connection with the production of the component by the taxpayer.</text></subparagraph></paragraph> <paragraph id="H9326F679DACC42E091DCD362E472EE1F"><enum>(3)</enum><header>Base credit percentage</header> <subparagraph id="H1E3DDD27CC1E45E4A672EC377CC3E61F"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraphs (B) and (C), the base credit percentage shall be 30 percent.</text></subparagraph> 
<subparagraph id="H33D75AEC88F9465586E22E8F3CB1C37E"><enum>(B)</enum><header>Increased base credit percentage for certain eligible components</header><text>The base credit percentage shall be 35 percent in the case of the final production of—</text> <clause id="HDD1AA9D3F1474594915111325201E117"><enum>(i)</enum><text>a drug substance, </text></clause> 
<clause id="H98F861F517314DC49489FAFCC26B1F14"><enum>(ii)</enum><text display-inline="yes-display-inline">a drug product, or </text></clause> <clause id="H83F86B4570E646FE9A84C7C9FC37CB97"><enum>(iii)</enum><text display-inline="yes-display-inline">a biological product.</text></clause></subparagraph> 
<subparagraph id="H8EA17042A57C4E159CABA0F1EA6C357B" commented="no"><enum>(C)</enum><header>Domestic content bonus credit</header> 
<clause id="HD48155E9F4234A06A0E699103640CE25" commented="no"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of an eligible component which contains domestic content, the base credit percentage determined under this paragraph (determined without regard to this subparagraph) shall be increased by an amount equal to—</text> <subclause id="H4DA9330E4DE34A33BC5725F7C0D12220" commented="no"><enum>(I)</enum><text>the domestic content percentage, multiplied by</text></subclause> 
<subclause id="HCDE7FF0D2D614F48A8E5B2868B6A911C" commented="no"><enum>(II)</enum><text>0.20.</text></subclause></clause> <clause id="H65ABDDE8C203461FA30D6012A247DEC4" commented="no"><enum>(ii)</enum><header>Domestic content percentage</header><text>For purposes of this paragraph, the term <quote>domestic content percentage</quote> means the percentage of the total cost of the bill of materials of the eligible component that is attributable to materials and components that were produced in the United States.</text></clause> 
<clause id="HE68B53F4E3CF4D409A240A9F82D3BB58" commented="no"><enum>(iii)</enum><header>Documentation rules</header> 
<subclause id="HA57E0DCAACEB40BDA1AC6C809D345EC3" commented="no"><enum>(I)</enum><header>Recordkeeping</header><text>No domestic content bonus credit shall be determined under this subparagraph unless the taxpayer provides documentation supporting the domestic content percentage (in such form and manner as the Secretary shall prescribe). </text></subclause> <subclause id="H03B78E90EF35465F9072FC16FB78768C" commented="no"><enum>(II)</enum><header>Certification by unrelated party</header><text display-inline="yes-display-inline">In the case of materials or components provided to the taxpayer by an unrelated party, the Secretary shall accept certification (in such form and manner as the Secretary shall prescribe) by such unrelated party that the materials or components were produced in the United States. </text></subclause></clause></subparagraph></paragraph> 
<paragraph id="HA0245FD304B049448702B7095460CEC6"><enum>(4)</enum><header>Phaseout</header> 
<subparagraph id="H4DEFB67FD66A4FD2B1E7A5E4684CF921"><enum>(A)</enum><header>In general</header><text>In the case of any eligible component sold after December 31, 2029, the amount determined under this subsection with respect to such component shall be equal to the product of—</text> <clause id="HD25A46056CAD43CF8F4DF512450CBAFC"><enum>(i)</enum><text>the amount determined under paragraph (1) with respect to such component (determined without regard to this paragraph after the application of paragraphs (2) and (3)), multiplied by</text></clause> 
<clause id="H8224B227BCB34F8BB1FF19A42D747230"><enum>(ii)</enum><text>the phaseout percentage under subparagraph (B).</text></clause></subparagraph> <subparagraph id="H38BAEC50730043C0BE88B9AB2F94E26E"><enum>(B)</enum><header>Phaseout percentage</header><text>The phase out percentage under this subparagraph is equal to—</text> 
<clause id="HD2D481768CA94322A6A8FCD60E9317F3"><enum>(i)</enum><text>in the case of an eligible component sold during calendar year 2030, 75 percent,</text></clause> <clause id="H017001755F754E73824AEB49CB52F17E"><enum>(ii)</enum><text>in the case of an eligible component sold during calendar year 2031, 50 percent,</text></clause> 
<clause id="HD40A311A77164D918FF350C14C161B3F"><enum>(iii)</enum><text>in the case of an eligible component sold during calendar year 2032, 25 percent,</text></clause> <clause id="HB4A6124C93EE49F895C1A06E14D841EF"><enum>(iv)</enum><text>in the case of an eligible component sold after December 31, 2032, 0 percent.</text></clause></subparagraph></paragraph></subsection> 
<subsection id="H2258361A650E4110ADDFF5902A45AA66"><enum>(c)</enum><header>Definitions</header><text>For purposes of this section—</text> <paragraph id="HFBFC4F800E1941799BBA94B2883D795D"><enum>(1)</enum><header>Eligible component</header> <subparagraph id="HF0FAED78CE31404494BE29E4DFFC9594"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraphs (B) and (C), the term <quote>eligible component</quote> means—</text> 
<clause id="HD704C96C9AEA47F79771CEB44919341D"><enum>(i)</enum><text>an approved generic drug,</text></clause> <clause id="HCD12B98F4E7F470CA0E47979EF1EFB44"><enum>(ii)</enum><text>a licensed biosimilar, and</text></clause> 
<clause id="H06432CE8B8424841B0ECCCFFF120F5E8"><enum>(iii)</enum><text>any drug substance, intermediate, raw material, starting material, reagent, component, in-process material, inactive ingredient, container closure system, packaging, quality testing, or other material or service used, or sold with intention for use, in the production of an approved generic drug or a licensed biosimilar.</text></clause></subparagraph> <subparagraph id="HAB40EEFE965B4F6EA6D7C7EC75A86EFC" display-inline="no-display-inline"><enum>(B)</enum><header>Exclusion of certain components</header><text>The term <quote>eligible component</quote> shall not include a component any portion of the production of which occurred at a facility which is the subject of a warning letter—</text> 
<clause id="H9691985A3341460E8E3A70A4EE6E3C3D"><enum>(i)</enum><text>which was issued by the Food and Drug Administration on or after September 1, 2009, and</text></clause> <clause id="H5290D26A06F04A07A7D79BCB6FB08AC3"><enum>(ii)</enum><text>with respect to which the Food and Drug Administration has not issued a close-out letter.</text></clause></subparagraph> 
<subparagraph id="H43252CF7F85E4808AB0417D5047D33EB"><enum>(C)</enum><header>Application with other credits</header><text>The term <quote>eligible component</quote> shall not include any property which is produced at a facility if the basis of any property which is part of such facility is taken into account for purposes of the credit allowed under section 48F after the date of the enactment of this section.</text></subparagraph></paragraph> <paragraph id="H05F5352192C540568283E32B6209A40B"><enum>(2)</enum><header>Approved generic drug</header><text>The term <quote>approved generic drug</quote> means—</text> 
<subparagraph id="H11177947E2A843E2A4EF0BB0DBDAB1F6"><enum>(A)</enum><text>a drug for which an approval of an application filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is in effect, or</text></subparagraph> <subparagraph id="H566369CBD3614607B1CC1328301A14C0"><enum>(B)</enum><text display-inline="yes-display-inline">an authorized generic drug.</text></subparagraph></paragraph> 
<paragraph id="H5283BD500C9949C8B1984F9D26C947FB"><enum>(3)</enum><header>Authorized generic drug; drug substance; drug product</header><text display-inline="yes-display-inline">The terms <quote>authorized generic drug</quote>, <quote>drug substance</quote>, and <quote>drug product</quote> have the respective meanings given such terms in section 314.3 of title 21, Code of Federal Regulations (or any successor regulation). </text></paragraph> <paragraph id="HFBDA9177821A46ACB16D33B0BD07FA6F" commented="no"><enum>(4)</enum><header>Biological product</header><text display-inline="yes-display-inline">The term <quote>biological product</quote> has the meaning given such term in section 351(i)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)(1)</external-xref>).</text></paragraph>
<paragraph id="H2B958039048B45A98328CEDAD8DEE9E8"><enum>(5)</enum><header>Licensed biosimilar</header><text display-inline="yes-display-inline">The term <quote>licensed biosimilar</quote> means a biological product for which a biologics license has been issued under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>). </text> </paragraph> <paragraph id="H8BCAE28C0C4147E7B1D306B2CC7F0738"><enum>(6)</enum><header>Produced in the United States</header><text>The term <quote>produced in the United States</quote> means that all the production of the material or component takes place in the United States, regardless of the origin of the subcomponents of such material or component. </text></paragraph>
<paragraph id="H3FE826E4D5A0459C89B10E284CB70BFD"><enum>(7)</enum><header>Production</header><text display-inline="yes-display-inline">The term <quote>production</quote> means all steps in the manufacture, propagation, and preparation of an eligible component, including synthesis, mixing, granulating, milling, molding, lyophilizing, tableting, encapsulating, coating, sterilizing, testing, filling, labeling, packaging, and storage prior to release by the manufacturer.</text> </paragraph></subsection> <subsection id="HF75430FF70C54C8EA86C235B2996F209"><enum>(d)</enum><header>Special rules</header><text display-inline="yes-display-inline">Rules similar to the rules of paragraphs (1), (3), and (4) of section 45X(d) shall apply. </text> </subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H000BFB723099422E8A6EECE21988FDFC"><enum>(b)</enum><header>Elective payment</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/6417">Section 6417(a)</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new paragraph:</text> <quoted-block style="OLC" id="HB7E3A745AC9041C089F3E2B94181244F" display-inline="no-display-inline"> <paragraph id="H9FEB451E2A4B4EAFADDBD9F9E94218FA"><enum>(13)</enum><text display-inline="yes-display-inline">The generic drugs and biosimilars production credit determined under section 45BB. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="HCB77DEE759824BDFA19EAB60F85FC8D5"><enum>(c)</enum><header>Conforming amendments</header> 
<paragraph id="HFFFB289D5B7A4EB2B37ED2A648168E1D"><enum>(1)</enum><text><external-xref legal-doc="usc" parsable-cite="usc/26/38">Section 38(b)</external-xref> of the Internal Revenue Code of 1986 is amended—</text> <subparagraph id="HA12CF5843E004EFB93C6F97D5213761E"><enum>(A)</enum><text>in paragraph (40), by striking <quote>plus</quote> at the end, and</text></subparagraph> 
<subparagraph id="HEEDE813AF2574C00AF858BD44CD312D1"><enum>(B)</enum><text>in paragraph (41), by striking the period at the end and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text> <quoted-block id="H1D7B5B91376945C6BBC0F29613BEEB8F" style="OLC"> <paragraph id="H8574D330F0414491BF9DB2F3D4B751B3"><enum>(42)</enum><text>the generic drugs and biosimilars production credit determined under section 45BB(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> 
<paragraph id="H2034F94D0688463492F26B77AD3CA772"><enum>(2)</enum><text>The table of sections for subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:</text> <quoted-block id="HAADA41855B69412EBAFB9C9AE954D09B" style="OLC"> <toc regeneration="no-regeneration"> <toc-entry level="section">Sec. 45BB. Generic drugs and biosimilars production credit.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> <subsection id="H95E1FE3EA0F04B4FB3DF72FACB6F1E52"><enum>(d)</enum><header>Effective date</header><text>The amendments made by this section shall apply to generic drugs and biologics produced after the date of enactment of this Act.</text></subsection></section> 
<section id="HBC31822995DB4C1081610F505364C236"><enum>3.</enum><header>Generic drugs and biosimilars investment credit</header> 
<subsection id="HAD01C2D3F09948F5B4AC0A169709A9FF"><enum>(a)</enum><header>In general</header><text>Subpart E of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by inserting after section 48E the following new section:</text> <quoted-block id="H873ADF4661254759BFFF678F8F524531" style="OLC"> <section id="HB7581B261F4C4BDFB1BFF1541D94D5C1"><enum>48F.</enum><header>Generic drugs and biosimilars investment credit</header> <subsection id="H30A71DB354DB439A9788CF3E5B94A960"><enum>(a)</enum><header>Establishment of credit</header><text>For purposes of section 46, the generic drugs and biosimilars investment credit for any taxable year is an amount equal to 25 percent of the qualified investment for such taxable year with respect to any qualified facility of an eligible taxpayer.</text></subsection> 
<subsection id="HF7AE9019921045C5A6C537CFC7CFC611"><enum>(b)</enum><header>Qualified investment</header> 
<paragraph id="HF370A5D1BEC74EDEABED1CBE383F173A"><enum>(1)</enum><header>In general</header><text>For purposes of subsection (a), the qualified investment for any taxable year is the basis of any qualified property placed in service by the taxpayer during such taxable year which is part of a qualified facility.</text></paragraph> <paragraph id="H5416623D1FF9400C8DCF6FD88B3A750C"><enum>(2)</enum><header>Qualified property</header> <subparagraph id="H55E1123CE21B439AAD7AF0A0BE06D9B8"><enum>(A)</enum><header>In general</header><text>For purposes of this subsection, the term <quote>qualified property</quote> means property—</text> 
<clause id="HB46838E9093F4746B9EB1D4F0F4815F7"><enum>(i)</enum><text>which is tangible property,</text></clause> <clause id="HC6C47FBD595F46D0BDF88428958442F8"><enum>(ii)</enum><text>with respect to which depreciation (or amortization in lieu of depreciation) is allowable,</text></clause> 
<clause id="HF2B17EEC108C4B36AD77678E61A815A7"><enum>(iii)</enum><text>which is—</text> <subclause id="H5D79313C6D1A478FB5C3F4063212D512"><enum>(I)</enum><text>constructed, reconstructed, or erected by the taxpayer, or</text></subclause> 
<subclause id="HA6140575D69B469DBDD739454B34B02C"><enum>(II)</enum><text>acquired by the taxpayer if the original use of such property commences with the taxpayer, and</text></subclause></clause> <clause id="H7134DC9F86D942829FFC398E9346010D"><enum>(iv)</enum><text>which is integral to the operation of the qualified facility.</text></clause></subparagraph> 
<subparagraph id="HFC6F4B756AFC40A6B760CF4913B81F60"><enum>(B)</enum><header>Buildings and structural components</header> 
<clause id="H085A2AD24DFF4CCB9672BDEC1AF3612A"><enum>(i)</enum><header>In general</header><text>The term <quote>qualified property</quote> includes any building or its structural components which otherwise satisfy the requirements under subparagraph (A).</text></clause> <clause id="H60C2ECA3431648CDAF15088DFB9C6BA2"><enum>(ii)</enum><header>Exception</header><text>Clause (i) shall not apply with respect to a building or portion of a building used for offices, administrative services, or other functions unrelated to the production of eligible components.</text></clause></subparagraph></paragraph> 
<paragraph id="H5A06CF00BE08468198FB7427982A240D"><enum>(3)</enum><header>Qualified facility</header><text>For purposes of this section, the term <quote>qualified facility</quote> means a facility the primary purpose of which is the production of eligible components.</text></paragraph> <paragraph id="H58391198D8014A7D98C1BC11BD8D748C"><enum>(4)</enum><header>Coordination with rehabilitation credit</header><text>The qualified investment with respect to any qualified facility for any taxable year shall not include that portion of the basis of any property which is attributable to qualified rehabilitation expenditures (as defined in section 47(c)(2)).</text></paragraph> 
<paragraph id="H19E35228705E41A19532CCCC066375AE"><enum>(5)</enum><header>Certain progress expenditure rules made Applicable</header><text>Rules similar to the rules of subsections (c)(4) and (d) of section 46 (as in effect on the day before the date of the enactment of the Revenue Reconciliation Act of 1990) shall apply for purposes of subsection (a).</text></paragraph></subsection> <subsection id="H03DAB85682504993954AB8AB334866A9"><enum>(c)</enum><header>Definitions</header><text>For purposes of this section—</text> 
<paragraph id="HBBFE8232BCAF4310B588AF2ED76EDD7B"><enum>(1)</enum><header>Eligible taxpayer</header><text>The term <quote>eligible taxpayer</quote> means any taxpayer which—</text> <subparagraph id="H6DED68B98DEC4EE89A36AE3ED6C9E99A"><enum>(A)</enum><text>is not a foreign entity of concern (as defined in section 9901(8) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<external-xref legal-doc="usc" parsable-cite="usc/15/4651">15 U.S.C. 4651</external-xref>), and</text></subparagraph> 
<subparagraph id="HF18C818231CF4D8CA9590FD537505867"><enum>(B)</enum><text>has not made an applicable transaction (as defined in section 50(a)) during the taxable year.</text></subparagraph></paragraph> <paragraph id="H8D86A0920A5B414EB886E5510EBB9CB3"><enum>(2)</enum><header>Eligible component</header><text display-inline="yes-display-inline">The term <quote>eligible component</quote> has the meaning given such term in section 45BB(c)(1). </text> </paragraph> 
<paragraph id="HF168304F41CB465CBA227DA1AD7629F9"><enum>(3)</enum><header>Production</header><text display-inline="yes-display-inline">The term <quote>production</quote> has the meaning given such term in section 45BB(c)(6). </text> </paragraph></subsection> <subsection id="H6A37AE0C56904BB9990A7EB16F50805B"><enum>(d)</enum><header>Termination of credit</header><text>The credit allowed under this section shall not apply to property the construction of which begins after December 31, 2027.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H3AEFF4B024CD46D4BFE973DC85A0FCBD"><enum>(b)</enum><header>Elective payment</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/6417">Section 6417(a)</external-xref> of the Internal Revenue Code of 1986, as amended by section 2(b) of this Act, is amended by adding at the end the following new paragraph:</text> <quoted-block style="OLC" id="HB5543778C41C41508A7C8241273F9928" display-inline="no-display-inline"> <paragraph id="H03673CB415004289B3ED102794B9CE67"><enum>(14)</enum><text display-inline="yes-display-inline">The generic drugs and biosimilars investment credit determined under section 48F. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="HB1EE8D1C95954607AC1CF37C6345C6BD"><enum>(c)</enum><header>Conforming amendments</header> 
<paragraph id="HBEB7D9567CE94B19BE94AB4F4D7FEAFF"><enum>(1)</enum><text>Section 46 is amended—</text> <subparagraph id="H92344F1E11684B47ABE301A41F2FB250"><enum>(A)</enum><text>in paragraph (6), by striking <quote>and</quote> at the end,</text></subparagraph> 
<subparagraph id="H3F41D31B466E4060AF29B3427A1997EC"><enum>(B)</enum><text>in paragraph (7), by striking the period at the end and inserting <quote>, and</quote>, and</text></subparagraph> <subparagraph id="H315BCBF1969C402E8C34ACF62266376B"><enum>(C)</enum><text>by adding at the end the following:</text> 
<quoted-block id="H64E44CA61099449080C1F5C020A9DD55" style="OLC"> 
<paragraph id="HC9B22DF8792C4C02A84C68364D5D17B5"><enum>(8)</enum><text>the generic drugs and biosimilars investment credit.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph id="H00425D46BA6246D780051AC5131BA766"><enum>(2)</enum><text>Section 49(a)(1)(C) is amended—</text> 
<subparagraph id="H452887A5FF85473799C01ECA967F2556"><enum>(A)</enum><text>by striking <quote>and</quote> at the end of clause (vi),</text></subparagraph> <subparagraph id="H48557F536F3D4C2FB3765928265F4BCD"><enum>(B)</enum><text>by striking the period at the end of clause (vii) and inserting a comma, and</text></subparagraph> 
<subparagraph id="H06AF639C9B734ACDB342DAFB9394ED50"><enum>(C)</enum><text>by adding at the end the following new clause:</text> <quoted-block id="HD4644F225446453AA04D6CD48879C9EE" style="OLC"> <clause id="H0FC8785FA0CE43A6B2CB8336C18B28CA"><enum>(viii)</enum><text>the basis of any qualified property which is part of a qualified facility under section 48F.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> 
<paragraph id="HDD1EB200224944B185F18BFCC22293A9"><enum>(3)</enum><text>The table of sections for subpart E of part IV of subchapter A of chapter 1 is amended by inserting after the item relating to section 48E the following new item:</text> <quoted-block id="H967D09FBD79743308F67FCF6A6A22DE9" style="OLC"> <toc regeneration="no-regeneration"> <toc-entry level="section">48F. Generic drugs and biosimilars investment credit.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> <subsection id="HF2902CA8F4EE415BB13978EAD076E0A2"><enum>(d)</enum><header>Effective date</header><text>The amendments made by this section shall apply to property placed in service after December 31, 2025.</text></subsection></section> 
</legis-body></bill>

